Heart involvement in systemic sclerosis;Atteinte cardiaque de la sclérodermie systémique

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1938-1942

  Allanore, Yannick ^a,b   Kahan, André ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; COLCHICINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLECAINIDE ACETATE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCAINAMIDE; QUINIDINE;

BLOOD VESSEL REACTIVITY; DEFIBRILLATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY DYSFUNCTION; LONG TERM EXPOSURE; MICROCIRCULATION; MYOCARDIAL DISEASE; MYOSITIS; PERICARDIAL DISEASE; PROGNOSIS; RECURRENT DISEASE; REVIEW; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS; VALVULAR HEART DISEASE;

EID: 33845477050     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74928-4     Document Type: Review

References (30)

1. Clements PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG. Cardiac score. A semi-quantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1991; 34: 1371-80.
2. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43: 2437-44.
3. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al. Systemic Sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81: 139-53.
4. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Nitenberg A et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986; 314: 1397-1402.
5. Duboc D, Kahan A, Maziere B, Loc'h C, Crouzel C, Menkes CJ et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis: a positron emission tomographic study. Arthritis Rheum. 1991; 34: 198-203.
6. Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S et al. Evaluation of nifedipine efficacy on myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005; 64: 1268-73.
7. Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN Jr et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med. 1986; 105: 661-8.
8. Steen VD, Follansbee WP, Conte CG, Medsger TA Jr. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum. 1996; 39: 677-81.
9. Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens G et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med. 1984; 310: 142-8.
10. Kahan A, Nitenberg A, Foult JM, Amor B, Menkes CJ, Devaux JY et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985; 28: 637-46.
11. Ishida R, Murata Y, Sawada Y. Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000; 21: 729-734.
12. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Venot A et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther. 1990; 47: 483-9.
13. Panting JR, Gatehouse PD, Yang GZ, Firmin DN, Collins P, Pennell DJ et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002; 346: 1948-53.
14. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Guerin F et al. Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis. J Cardiovasc Pharmacol. 1990; 15: 249-53.
15. Hegedus I, Czirjak L. Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis. Clin Rheumatol. 1995; 14: 161-4.
16. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum. 2005; 34: 721-7.
17. Meune C, Allanore Y, Devaux JY, Dessault O, Duboc D, Weber S et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol. 2004; 31: 1941-5.
18. Meune C, Allanore Y, Pascal O, Devaux JY, Dessault O, Duboc D et al. Myocardial contractility is early affected in systemic sclerosis: A Tissue Doppler echocardiography study. Eur J Echocardiogr. 2005; 6: 351-7.
19. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG et al. NT-pro-B-type brain natriuretic peptide as a diagnostic marker of early pulmonary arterial hypertension and effects of calcium channel blockers in systemic sclerosis. Arthritis Rheum. 2003; 48: 3503-8.
20. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford). 2005; 44: 366-71.
21. Ferri C, Emdin M, Nielsen H, Bruhlmann P. Assessment of heart involvement. Clin Exp Rheumatol. 2003; 21(Suppl 29): S24-8.
22. Allali F, Alami M, Doghmi N, Mohatane A, Benomar M, Hajjaj-Hassouni N. Scleroderma complicated with tamponade during pregnancy. Joint Bone Spine. 2005; 72: 341-3.
23. Satoh M, Tokuhira M, Hama N, Hirakata M, Kuwana M, Akizuki M et al. Massive pericardial effusion in scleroderma: a review of five cases. Br J Rheumatol. 1995; 34: 564-7.
24. Follansbee WP, Curtiss EI, Rahko PS, Medsger TA Jr, Lavine SJ, Owens GR et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med. 1985; 79: 183-92.
25. Ferri C, Bernini L, Bongiorni MG, Levorato D, Viegi G, Bravi P et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum. 1985; 28: 1259-66.
26. Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA Jr et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988; 84: 1007-15.
27. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993; 125: 194-203.
28. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005; 112: 2012-6.
29. Allanore Y, Kahan A. Treatment of systemic sclerosis. Joint Bone Spine. 2006; 73: 363-8.
30. Allanore Y, Vignaux O, Arnaud L, Puechal X, Pavy S, Duboc D et al. Effects of corticosteroids and imumnosuppressors on idiopathic inflammatory myopathies-related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis. 2006; 65: 249-52.